TY - JOUR
T1 - Development of a novel scale to assess the quality of life in type 1 diabetic patients for beta cell replacement therapy
AU - Hatanaka, Nobuyo
AU - Takita, Morihito
AU - Yamaguchi, Takuhiro
AU - Kami, Masahiro
AU - Matsumoto, Shinichi
N1 - Funding Information:
This study was supported in part by the Health Labour Sciences Research Grant for Research on Basic Researches from the Japanese Ministry of Health, Labour and Welfare (H19-Trans-General-004) and All Saints Health Foundation (Fort Worth, TX). The authors thank the non-profit organization, Japan IDDM network, for its cooperation. The authors wish to thank Mr. Jeffrey A. SoRelle for editing this manuscript.
PY - 2011/6
Y1 - 2011/6
N2 - The main purpose of beta cell replacement therapy for type 1 diabetic patients is to improve their health-related quality of life (HR-QoL). Previous HR-QoL surveys for beta cell replacement therapy on the point of familial support and public understanding have not been studied adequately. We hypothesize that familial support and public understanding have a significant impact on HR-QoL of type 1 diabetic patients, and low HR-QoL assessed with a new scale is associated with seeking a new therapy. The initial questionnaire with 26 items was created after content validation based on 778 inquiries from patients or associates. One hundred five type 1 diabetic patients answered the questionnaire as well as separate questions about their opinions on beta cell replacement therapy. Finally, the new scale, named the Japanese Insulin-Dependent Diabetic Patient QoL (JAPID-QoL) scale, consisted of 19 items with the following three subscales: diabetes status, familial support and social acceptance. Cronbach's α for overall scale was 0. 878, and those for three subscales were over 0. 70. All items were satisfied with convergent validity. Lower scores on the JAPID-QoL scale were associated with higher interest in and acceptance of beta cell replacement therapy (Spearman's coefficients; r = -0. 25, p < 0. 001 and r = -0. 33, p < 0. 001, respectively) and also correlated with the necessity of psychosomatic care (r = -0. 49, p < 0. 001). Our newly proposed JAPID-QoL scale showed enough reliability and validity to assess HR-QoL of type 1 diabetic patients. The patients who had a low HR-QoL on the JAPID-QoL scale desired to receive beta cell replacement therapy and psychosomatic care.
AB - The main purpose of beta cell replacement therapy for type 1 diabetic patients is to improve their health-related quality of life (HR-QoL). Previous HR-QoL surveys for beta cell replacement therapy on the point of familial support and public understanding have not been studied adequately. We hypothesize that familial support and public understanding have a significant impact on HR-QoL of type 1 diabetic patients, and low HR-QoL assessed with a new scale is associated with seeking a new therapy. The initial questionnaire with 26 items was created after content validation based on 778 inquiries from patients or associates. One hundred five type 1 diabetic patients answered the questionnaire as well as separate questions about their opinions on beta cell replacement therapy. Finally, the new scale, named the Japanese Insulin-Dependent Diabetic Patient QoL (JAPID-QoL) scale, consisted of 19 items with the following three subscales: diabetes status, familial support and social acceptance. Cronbach's α for overall scale was 0. 878, and those for three subscales were over 0. 70. All items were satisfied with convergent validity. Lower scores on the JAPID-QoL scale were associated with higher interest in and acceptance of beta cell replacement therapy (Spearman's coefficients; r = -0. 25, p < 0. 001 and r = -0. 33, p < 0. 001, respectively) and also correlated with the necessity of psychosomatic care (r = -0. 49, p < 0. 001). Our newly proposed JAPID-QoL scale showed enough reliability and validity to assess HR-QoL of type 1 diabetic patients. The patients who had a low HR-QoL on the JAPID-QoL scale desired to receive beta cell replacement therapy and psychosomatic care.
KW - Familial support
KW - Quality of life
KW - Social acceptance
KW - Transplantation therapy
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=82355175832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82355175832&partnerID=8YFLogxK
U2 - 10.1007/s13340-011-0023-1
DO - 10.1007/s13340-011-0023-1
M3 - Article
AN - SCOPUS:82355175832
SN - 2190-1678
VL - 2
SP - 55
EP - 64
JO - Diabetology International
JF - Diabetology International
IS - 2
ER -
